PONVORY™ (ponesimod) HCP
PONVORY™ WAS PROVEN SUPERIOR AT REDUCING RELAPSES AND LESIONS VS AUBAGIO® IN A STUDY LASTING ~2 YEARS2
PONVORY™: an oral, once-daily, selective S1P1 therapy for relapsing MS in adults2-4†
No genetic testing; no first-dose monitoring for most patients§; no known food restrictions; ~7-day reversibility of lymphocyte count reduction, as seen in PK-PD assessments; 1-week elimination allows for pregnancy 7 days after stopping PONVORY™; no rapid elimination procedure required2
ARR = annualized relapse rate; GdE = gadolinium-enhancing; PD = pharmacodynamic; PK = pharmacokinetic; S1P1 = sphingosine-1-phosphate 1.
*Collected in 11/21 and is subject to change. This information does not provide advice or guarantee coverage or payment, is not intended to provide reimbursement advice, and is not intended to increase or maximize reimbursement by any payer. Legal requirements and plan information can be updated frequently. We strongly recommend contacting the plan for more information about current coverage, restrictions, or prerequisites that may apply.
†The exact mechanism by which PONVORY™ exerts therapeutic effects in MS is unknown but may involve reduction of lymphocyte migration into the central nervous system.2
‡As studied in OPTIMUM, a 108-week, randomized, double-blind, phase 3 study.2
§First-dose, 4-hour monitoring is recommended for patients with sinus bradycardia (heart rate <55 beats per minute), first- or second-degree atrioventricular block (Mobitz type I), or a history of myocardial infarction or heart failure occurring >6 months prior to treatment initiation and in stable condition.2